Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Lophius Biosciences GmbH. (7/18/11). "Press Release: Lophius Biosciences Closes Additional Financing Round with Current Investors Totalling 1.4 Million EUR".

Region Region Germany
Organisations Organisation Lophius Biosciences GmbH
  Organisation 2 S-Refit AG
  Group Sparkassen-Finanzgruppe (DE) [FICTIVE UNIT, NOT OFFICIAL GROUP!] (Group)
Products Product T-Track® CMV/EBV tests
  Product 2 diagnostics (medical/biological)
Index terms Index term Lophius–SEVERAL: investment, 201107 3rd financing round €1.4m S-Refit + HTGF + Bayernkapital
  Index term 2 Lophius–High-Tech Gründerfonds: investment, 201107 3rd financing round totalling €1.4m incl co-investor HTGF
Persons Person Lutz, Michael (GATC 201004– LifeCodexx AG CEO before Clinical Data/Cogenics before Epidauros before SuNyx)
  Person 2 Gilka-Bötzow, Bertram (S-Refit 201107)
     


Lophius Biosciences, a leading developer of novel, innovative T-cell-based diagnostic test systems, announced today closing of an additional financing round totaling 1.4 million EUR. All current financial investors, such as S-Refit, High-Tech Gründerfonds (HTGF) as well as Bayernkapital participated in this financing round. The funds will be used for the market introduction of the T-Track© CMV/EBV tests in the field of transplantation, for further development of a diagnostic test for the differential diagnosis of tuberculosis, as well as for the new development of a novel, blood-based multiple sclerosis test.

"We are very pleased to have been able to conclude this financing round with our existing investors in such a short time. Subsequent to the successful establishment of the company over the past year and the imminent conclusion of the test developments for our patented T-Track© CMV/EBV Tests, these new financial resources allow us to prepare for market entry of these tests from the beginning of 2012 with an effective team. Beyond this, we will now intensify the development of additional innovative diagnostic tests based on our patented technology platforms," said Dr. Michael Lutz, CEO of Lophius Biosciences.

"With the aid of the financing round in the precious year Lophius Biosciences has been able to develop from an essentially academic research company into a small, highly innovative and fully integrated diagnostic company within a very short timeframe. We are absolutely convinced that the Lophius' technologies and the products have a great potential to provide patients with large diagnostic benefits in our disease areas," amended Bertram Gilka-Bötzow of S-Refit, Lophius Biosciences' lead investor.


About Lophius Biosciences

Lophius Biosciences GmbH develops and markets innovative T-cell-based test systems for diagnostics and possible therapy control in the fields of transplantation, infection, and autoimmune diseases.


Contact:

Kerstin Maier
Phone: +49 941 6309 1972
E-Mail: kerstin.maier@lophius.de
www.lophius.de

   
Record changed: 2017-04-02

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Lophius Biosciences GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px




» top